-
1
-
-
0037222235
-
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: High incidence of early complete and major cytogenetic responses
-
DOI 10.1182/blood-2002-02-0545
-
Kantarjian HM, Cortes JE, OBrien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003;101:97-100. (Pubitemid 36025893)
-
(2003)
Blood
, vol.101
, Issue.1
, pp. 97-100
-
-
Kantarjian, H.M.1
Cortes, J.E.2
O'Brien, S.3
Giles, F.4
Garcia-Manero, G.5
Faderl, S.6
Thomas, D.7
Jeha, S.8
Rios, M.B.9
Letvak, L.10
Bochinski, K.11
Arlinghaus, R.12
Talpaz, M.13
-
2
-
-
33845444046
-
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
-
DOI 10.1056/NEJMoa062867
-
Druker BJ, Guilhot F, OBrien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417. (Pubitemid 44903745)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.23
, pp. 2408-2417
-
-
Druker, B.J.1
Guilhot, F.2
O'Brien, S.G.3
Gathmann, I.4
Kantarjian, H.5
Gattermann, N.6
Deininger, M.W.N.7
Silver, R.T.8
Goldman, J.M.9
Stone, R.M.10
Cervantes, F.11
Hochhaus, A.12
Powell, B.L.13
Gabrilove, J.L.14
Rousselot, P.15
Reiffers, J.16
Cornelissen, J.J.17
Hughes, T.18
Agis, H.19
Fischer, T.20
Verhoef, G.21
Shepherd, J.22
Saglio, G.23
Gratwohl, A.24
Nielsen, J.L.25
Radich, J.P.26
Simonsson, B.27
Taylor, K.28
Baccarani, M.29
So, C.30
Letvak, L.31
Larson, R.A.32
more..
-
3
-
-
2942593704
-
Optimizing treatment of chronic myeloid leukemia: A rational approach
-
DOI 10.1634/theoncologist.9-3-259
-
Stone RM. Optimizing treatment of chronic myeloid leukemia: a rational approach. Oncologist 2004;9:259-270. (Pubitemid 38756875)
-
(2004)
Oncologist
, vol.9
, Issue.3
, pp. 259-270
-
-
Stone, R.M.1
-
4
-
-
58549109605
-
Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase
-
Kiguchi T, Tauchi T, Ito Y, Miyazawa K, Kimura Y, Ohyashiki K. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. Leuk Res 2009;33:506-508.
-
(2009)
Leuk Res
, vol.33
, pp. 506-508
-
-
Kiguchi, T.1
Tauchi, T.2
Ito, Y.3
Miyazawa, K.4
Kimura, Y.5
Ohyashiki, K.6
-
5
-
-
0037438640
-
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571
-
DOI 10.1182/blood.V101.2.690
-
Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-698. (Pubitemid 36077594)
-
(2003)
Blood
, vol.101
, Issue.2
, pp. 690-698
-
-
Donato, N.J.1
Wu, J.Y.2
Stapley, J.3
Gallick, G.4
Lin, H.5
Arlinghaus, R.6
Talpaz, M.7
-
6
-
-
31344472945
-
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)
-
DOI 10.1016/j.critrevonc.2005.06.007, PII S1040842805001459
-
Walz C, Sattler M. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML). Crit Rev Oncol Hematol 2006;57:145-164. (Pubitemid 43140744)
-
(2006)
Critical Reviews in Oncology/Hematology
, vol.57
, Issue.2
, pp. 145-164
-
-
Walz, C.1
Sattler, M.2
-
7
-
-
0035800507
-
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
-
DOI 10.1126/science.1062538
-
Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880. (Pubitemid 32743979)
-
(2001)
Science
, vol.293
, Issue.5531
, pp. 876-880
-
-
Gorre, M.E.1
Mohammed, M.2
Ellwood, K.3
Hsu, N.4
Paquette, R.5
Nagesh Rao, P.6
Sawyers, C.L.7
-
8
-
-
0034254368
-
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
-
Mahon FX, Deininger MW, Schultheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000;96: 1070-1079. (Pubitemid 30616875)
-
(2000)
Blood
, vol.96
, Issue.3
, pp. 1070-1079
-
-
Mahon, F.X.1
Deininger, M.W.N.2
Schultheis, B.3
Chabrol, J.4
Reiffers, J.5
Goldman, J.M.6
Melo, J.V.7
-
9
-
-
0037443754
-
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models
-
DOI 10.1182/blood.V101.6.2368
-
Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-2373. (Pubitemid 36304670)
-
(2003)
Blood
, vol.101
, Issue.6
, pp. 2368-2373
-
-
Mahon, F.-X.1
Belloc, F.2
Lagarde, V.3
Chollet, C.4
Moreau-Gaudry, F.5
Reiffers, J.6
Goldman, J.M.7
Melo, J.V.8
-
10
-
-
1642494654
-
Absolute Bioavailability of Imatinib (Glivec®) Orally versus Intravenous Infusion
-
DOI 10.1177/0091270003262101
-
Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 2004;44:158-162. (Pubitemid 38114314)
-
(2004)
Journal of Clinical Pharmacology
, vol.44
, Issue.2
, pp. 158-162
-
-
Peng, B.1
Dutreix, C.2
Mehring, G.3
Hayes, M.J.4
Ben-Am, M.5
Seiberling, M.6
Pokorny, R.7
Cupdeville, R.8
Lloyd, P.9
-
11
-
-
24344482346
-
Clinical pharmacokinetics of imatinib
-
DOI 10.2165/00003088-200544090-00001
-
Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879-894. (Pubitemid 41252840)
-
(2005)
Clinical Pharmacokinetics
, vol.44
, Issue.9
, pp. 879-894
-
-
Peng, B.1
Lloyd, P.2
Schran, H.3
-
12
-
-
0032528339
-
Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia
-
Pallisgaard N, Hokland P, Riishoj DC, Pedersen B, Jorgensen P. Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia. Blood 1998;92:574-588. (Pubitemid 28323721)
-
(1998)
Blood
, vol.92
, Issue.2
, pp. 574-588
-
-
Pallisgaard, N.1
Hokland, P.2
Riishoj, D.C.3
Pedersen, B.4
Jorgensen, P.5
-
13
-
-
26444595727
-
Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry
-
DOI 10.1097/01.ftd.0000175973.71140.91
-
Titier K, Picard S, Ducint D, et al. Quantification of imatinib in human plasma by high-performance liquid chromatography- tandem mass spectrometry. Ther Drug Monit 2005;27: 634-640. (Pubitemid 41437643)
-
(2005)
Therapeutic Drug Monitoring
, vol.27
, Issue.5
, pp. 634-640
-
-
Titier, K.1
Picard, S.2
Ducint, D.3
Teilhet, E.4
Moore, N.5
Berthaud, P.6
Mahon, F.-X.7
Molimard, M.8
-
14
-
-
10744229080
-
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
-
DOI 10.1056/NEJMoa030513
-
Hughes TP, Kaeda J, Branford S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. N Engl J Med 2003;349:1423-1432. (Pubitemid 37211057)
-
(2003)
New England Journal of Medicine
, vol.349
, Issue.15
, pp. 1423-1432
-
-
Hughes, T.P.1
Kaeda, J.2
Branford, S.3
Rudzki, Z.4
Hochhaus, A.5
Hensley, M.L.6
Gathmann, I.7
Bolton, A.E.8
Van Hoomissen, I.C.9
Goldman, J.M.10
Radich, J.P.11
-
15
-
-
0028813711
-
Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service
-
Kantarjian HM, Smith TL, OBrien S, Beran M, Pierce S, Talpaz M. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995;122: 254-261.
-
(1995)
Ann Intern Med
, vol.122
, pp. 254-261
-
-
Kantarjian, H.M.1
Smith, T.L.2
Obrien, S.3
Beran, M.4
Pierce, S.5
Talpaz, M.6
-
16
-
-
34147174980
-
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
-
DOI 10.1182/blood-2006-07-036012
-
Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496-3499. (Pubitemid 46572540)
-
(2007)
Blood
, vol.109
, Issue.8
, pp. 3496-3499
-
-
Picard, S.1
Titier, K.2
Etienne, G.3
Teilhet, E.4
Ducint, D.5
Bernard, M.-A.6
Lassalle, R.7
Marit, G.8
Reiffers, J.9
Begaud, B.10
Moore, N.11
Molimard, M.12
Mahon, F.-X.13
-
17
-
-
43249083718
-
Imatinib pharmacokinetics and its correlation with response and safety in chronicphase chronic myeloid leukemia: A subanalysis of the IRIS study
-
Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronicphase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022-4028.
-
(2008)
Blood
, vol.111
, pp. 4022-4028
-
-
Larson, R.A.1
Druker, B.J.2
Guilhot, F.3
-
18
-
-
57049115901
-
Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels
-
Forrest DL, Trainor S, Brinkman RR, et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 2009;33:271-275.
-
(2009)
Leuk Res
, vol.33
, pp. 271-275
-
-
Forrest, D.L.1
Trainor, S.2
Brinkman, R.R.3
-
19
-
-
67049087117
-
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study
-
Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 2009;113:5401-5411.
-
(2009)
Blood
, vol.113
, pp. 5401-5411
-
-
Noens, L.1
Van Lierde, M.A.2
De Bock, R.3
-
20
-
-
67649218742
-
Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: A report by the Nagasaki CML Study Group
-
Sakai M, Miyazaki Y, Matsuo E, et al. Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group. Int J Hematol 2009; 89:319-325.
-
(2009)
Int J Hematol
, vol.89
, pp. 319-325
-
-
Sakai, M.1
Miyazaki, Y.2
Matsuo, E.3
-
21
-
-
33846818881
-
Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML)
-
DOI 10.1016/j.leukres.2006.05.019, PII S0145212606002037
-
Horikoshi A, Takei K, Sawada S. Relationship between daily dose of imatinib per square meter and its plasma concentration in patients with chronic-phase chronic myeloid leukemia (CML). Leuk Res 2007;31:574-575. (Pubitemid 46210044)
-
(2007)
Leukemia Research
, vol.31
, Issue.4
, pp. 574-575
-
-
Horikoshi, A.1
Takei, K.2
Sawada, S.3
|